Jacobo Mintzer to Antipsychotic Agents
This is a "connection" page, showing publications Jacobo Mintzer has written about Antipsychotic Agents.
Connection Strength
2.321
-
Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opin Pharmacother. 2008 Oct; 9(14):2537-43.
Score: 0.269
-
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
Score: 0.256
-
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
Score: 0.253
-
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
Score: 0.225
-
A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin. 2004 Sep; 20(9):1483-91.
Score: 0.203
-
Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol. 2003 Dec; 16(4):199-206.
Score: 0.193
-
Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol Bull. 2003; 37(4):116-32.
Score: 0.181
-
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. Am J Psychiatry. 2017 04 01; 174(4):362-369.
Score: 0.118
-
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
Score: 0.089
-
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
Score: 0.086
-
The many faces of psychosis in the elderly. Curr Opin Psychiatry. 2007 Nov; 20(6):551-8.
Score: 0.063
-
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
Score: 0.061
-
Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb; 4(1):81-93.
Score: 0.060
-
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
Score: 0.058
-
Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies. J Clin Psychiatry. 2006; 67 Suppl 10:3-5.
Score: 0.056
-
The search for better noncholinergic treatment options for Alzheimer's disease. J Clin Psychiatry. 2003; 64 Suppl 9:18-22.
Score: 0.045
-
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002 Apr; 26(4):494-504.
Score: 0.043
-
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb; 60(2):107-15.
Score: 0.034
-
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry. 1996; 57 Suppl 7:55-63; discussion 73-5.
Score: 0.028